Trial
NCT03723551
Study to Assess Safety, Tolerability and Efficacy of Afabicin in The Treatment of Participants With Bone or Joint Infection Due to Staphylococcus
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Debiopharm International SA
Collaborators
—
Condition
Bone or Joint Infection
Intervention
Afabicin
Why stopped
This trial was concluded for strategic reasons.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-01